Oncolytics Biotech Inc T.ONC

Early HER2-Targeted Therapies in Breast Cancer offers hope

[Noteable]

https://www.biospace.com/article/releases/her2-targeted-therapies-introduced-early-in-breast-cancer-treatment-offering-hope-for-patients/

Biotech^® and SOLTI-Innovative Cancer Research today announced new clinical biomarker data demonstrating pelareorep's immunotherapeutic effects, synergy with checkpoint inhibition, and potential to improve the outlook for patients with HR+/HER2- breast cancer. 

"The latest data from AWARE-1 further demonstrate pelareorep's potential to improve clinical outcomes in breast cancer patients through its ability to activate T cells and remodel the tumor microenvironment," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer of Oncolytics. "

.... perhaps even more impressive, 100% of evaluable pelareorep-treated patients had a favorable Risk of Recurrence Score (ROR-S) compared to 55% at baseline. Together, these latest AWARE-1 results further establish pelareorep's ability to attack tumors through multiple mechanisms."

[Noteable]

Statistical significance was achieved (p-value=0.04) between the 2 study cohorts involving: Cohort 1 = pela + letrozole; and Cohort 2 = pela + letrozole + atezo. Also an association between decreased post-treatment T cell diversity and pre- vs. post-treatment increases in TILs was observed in both cohorts, reaching significance in C2 (p-value=0.01). These identified changes in

[Noteable]

Clarification : digital signal processing = digital spatial profiling (Nanostring's nCounter® system) which provides a better characterization and understanding of tumor heterogeneity and the tumor micro-environment (TME), enabling the improvement of patient therapy and the identification of potential biomarker signatures.